|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:alternativeTo
|
gptkb:Viagra
gptkb:Levitra
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
G04BE08
|
|
gptkbp:availableOn
|
gptkb:tablet
|
|
gptkbp:brand
|
gptkb:Adcirca
|
|
gptkbp:CASNumber
|
171596-29-5
|
|
gptkbp:chemicalFormula
|
C22H19N3O4
|
|
gptkbp:color
|
yellow
|
|
gptkbp:contraindication
|
nitrate medications
severe heart disease
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
gptkb:ICOS
|
|
gptkbp:discoveredBy
|
gptkb:Glaxo_Wellcome
|
|
gptkbp:drugClass
|
PDE5 inhibitor
|
|
gptkbp:duration
|
up to 36 hours
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:tadalafil
|
|
gptkbp:halfLife
|
17.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cialis
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
nitrates
alpha-blockers
antihypertensives
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketedAs
|
2003 (US)
2002 (Europe)
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:maximumDose
|
20 mg per day
|
|
gptkbp:mechanismOfAction
|
inhibits phosphodiesterase type 5
|
|
gptkbp:notRecommendedFor
|
gptkb:women
children
|
|
gptkbp:patentExpired
|
2017 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
adult males
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:shape
|
almond-shaped
|
|
gptkbp:sideEffect
|
headache
back pain
muscle aches
nasal congestion
dyspepsia
flushing
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:usedFor
|
gptkb:benign_prostatic_hyperplasia
erectile dysfunction
|
|
gptkbp:bfsParent
|
gptkb:礼来
|
|
gptkbp:bfsLayer
|
5
|